CFO interim
Imunon, Inc. names Josh Blacher interim CFO
Imunon, Inc. reported in a Form 8-K filed June 30, 2026 that Josh Blacher was named interim interim Chief Financial Officer, effective July 1, 2026.
In the filing's words
As a result of Mr. Church’s retirement, effective July 1, 2026, the Company appointed Josh Blacher to serve as the Company’s new interim Chief Financial Officer under a master services agreement (the “Agreement”), dated June 24, 2026, between the Company and Danforth Health, Inc., a financial advisory services firm (“Danforth”).
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Imunon, Inc. (IMNN) |
|---|---|
| Event | Interim |
| Incoming | Josh Blacher |
| Outgoing | Jeffrey Church |
| Title in the filing | interim Chief Financial Officer |
| Effective | July 1, 2026 |
| 8-K filed | June 30, 2026 |
| Internal promotion | No |
| Prior role (per filing) | employee of Danforth, Danforth Health, Inc. |
| SEC CIK | 0000749647 |
Imunon, Inc. reported this change in a Form 8-K, Item 5.02, filed June 30, 2026. The filing's own words are quoted above.
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Josh Blacher? Send a correction with the primary source.